Keyphrases
Hypovitaminosis D
97%
Metabolic Syndrome
95%
Type 2 Diabetic Patients
82%
Type 2 Diabetes Mellitus (T2DM)
63%
Glycemic Control
55%
Spain
51%
Bariatric Surgery
47%
Sex at Birth
47%
Vitamin D Status
32%
Diabetes
32%
Hypoglycemia
30%
First Trimester
30%
Confidence Interval
29%
Odds Ratio
26%
25(OH)D Concentration
24%
Antrum
23%
Dense LDL
23%
Individualized Glycemic Targets
23%
Glycemic Targets
23%
Stages of Change
23%
Inositol
23%
Glucose Homeostasis
23%
Meta-analysis of Randomized Controlled Trials
23%
Weight Management
23%
Laparoscopic Sleeve Gastrectomy
23%
Systematic Meta-analysis
23%
Randomized Trial
23%
GLP-1 Receptor Agonist
23%
Prandial
23%
Weight Loss Outcomes
23%
Gastric Emptying
23%
Lipid-lowering Treatment
23%
Electronegative LDL
23%
Apolipoprotein A-I (ApoA-I)
23%
Change Process
23%
Diabetic Patients
23%
High-density Lipoprotein Cholesterol (HDL-C)
23%
Cirrhosis
23%
Type 1 Diabetes Mellitus (T1DM)
23%
Truncated Forms
23%
Familial Combined Hyperlipidemia
23%
Low-density Lipoprotein
23%
Inflammatory Effects
23%
Primary Care Patients
23%
Type I Diabetes
23%
Levothyroxine
23%
Thyrotropin
23%
Isolated Hypercholesterolemia
23%
Degree of Obesity
23%
Hemoglobin A1c (HbA1c)
22%
Pharmacology, Toxicology and Pharmaceutical Science
Hypovitaminosis D
100%
Metabolic Syndrome X
95%
Non Insulin Dependent Diabetes Mellitus
74%
Diabetes Mellitus
64%
Vitamin D
53%
Inflammation
51%
Familial Hyperlipemia
47%
Low Density Lipoprotein
44%
Hemoglobin A1c
44%
High Density Lipoprotein
40%
Hypoglycemia
35%
Triacylglycerol
31%
Fatty Acid
27%
Clusterin
27%
Lipoprotein
26%
Omeprazole
23%
Inositol
23%
Insulin Dependent Diabetes Mellitus
23%
Randomized Controlled Trial
23%
Glucagon Like Peptide 1 Receptor Agonist
23%
Hypercholesterolemia
23%
Cell Receptor
23%
Cytotoxicity
23%
Antidiabetic Agent
16%
Enzyme-Linked Immunosorbent Assay
15%
Dyslipidemia
15%
Normal Human
13%
Disease
13%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
13%
C Reactive Protein
13%
Prevalence
11%
25 Hydroxyvitamin D
11%
Insulin Resistance
11%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Cytokine
10%
Coronary Artery Disease
9%
Ceramide
9%
Cross-Sectional Study
8%
Glycosylated Hemoglobin
7%
Maternal Diabetes Mellitus
7%
Very Low Density Lipoprotein
7%
Adverse Event
7%
Morbid Obesity
7%
Scavenger Receptor
7%
Fibronectin
7%
Glycosaminoglycan
7%
Serum Amyloid A
7%
Low Density Lipoprotein Receptor
7%
Cross Sectional Study
7%
Obesity
6%
Medicine and Dentistry
Sex Ratio
47%
Patient with Type 2 Diabetes
47%
Diabetes Mellitus
33%
First Trimester Pregnancy
30%
Primary Health Care
28%
Maturity Onset Diabetes of the Young
27%
Glycemic Control
27%
Bariatric Surgery
27%
Hypoglycemia
26%
Diabetes
26%
Hemoglobin A1c
24%
Levothyroxine
23%
Glycemic
23%
Hypovitaminosis D
23%
Liver Cirrhosis
23%
Adipose Tissue
23%
Thyrotropin
23%
Stomach Emptying
23%
Omeprazole
23%
Cytotoxicity
23%
Clusterin
23%
Laparoscopic Sleeve Gastrectomy
23%
Cardiac Muscle Cell
23%
Metabolic Syndrome
23%
Insulin Dependent Diabetes Mellitus
23%
Odds Ratio
23%
Neonatal Infant
18%
Fatty Acid
14%
Individualization
13%
Antidiabetic Agent
12%
Vitamin D
11%
Supplementation
11%
Pylorus
10%
Logistic Regression Analysis
9%
Ceramide
9%
Coronary Artery Disease
9%
Target Organ
9%
Hypothyroidism
5%
Cardiovascular System
5%
Autoimmunity
5%
Medicine
5%
Thyroid Gland
5%